Targeted Protein Degradation Market Growing at 20.7% CAGR to Hit USD 3547.91 million by 2034 | PMR

New York, USA, Dec. 09, 2024 (GLOBE NEWSWIRE) — Market Overview

The global targeted protein degradation market size is projected to grow from USD 541.98 million in 2024 to USD 3547.91 million by 2034, at a CAGR of 20.7%, according to a new report by Polaris Market Research.

Targeted protein degradation assimilates the cell’s organic ejection system to discard disease-generating proteins and is suitable for varied therapeutic regions involving oncology, dermatology, immunology, neuroscience, and respiratory illness. As a completely new perspective, it offers aspiration of illnesses formerly considered to be undruggable. Degrading instead of impeding a target protein provides many benefits, such as a more productive drug response at lower doses and a more accurate mediation with possibly decreased ramifications and illness aversion.

Download Free Sample PDF Copy of the Report:

https://www.polarismarketresearch.com/industry-analysis/targeted-protein-degradation-market/request-for-sample?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01

Key Insights from Report

• The market for targeted protein degradation is significantly shaped by its motive to confront illnesses by targeting and diminishing breaking down or disease-engendering proteins that conventional therapies might not productively confront.
• The targeted protein degradation market segmentation is mainly based on type, therapeutic area, route of administration, and region.
• Based on type, the proteolysis-targeting chimeric molecules (PROTACs) segment is expected to experience the highest CAGR during the forecast period.
• By region, the report provides market insights into Asia Pacific, Europe, North America, Latin America, and the Middle East & Africa.

Targeted Protein Degradation Market Scope

Market’s Growth Drivers

Earmarking Oncogenic Proteins: Targeted protein degradation is surfacing as a favorable method to confront the restrictions of conventional cancer therapies, especially since it is utilized for earmarking oncogenic proteins that drive cancer advancement. As per a 2023 study issued in Nature Reviews Drug Discovery, 60% of the agile TPD projects are concentrated on oncology-connected targets. This augmentation is propelled by TPD therapies to personally deteriorate cancer-connected proteins that are arduous to earmark with traditional drugs, contributing to targeted protein degradation market growth.

Surge in Neurological Illnesses: There is a growing concentration on petitioning TPD technologies to handle neurological illnesses. Proteins enmeshed in neurodegenerative illnesses such as Alzheimer’s and Parkinson’s are growingly being targeted for degradation to relieve illness indications or retard progression. An evaluated article in Cell Reports (2023) underscores that an additional 20% of current TPD research enterprises are targeted at neurodegenerative diseases.

Strategic Alliances between Pharmaceutical and Biotechnology Firms: Tactical associations and alliances between pharmaceutical firms and biotechnology organizations are speedily escalating in the market. These associations are important for progressing research, allocating technological proficiency, and speeding the advancement of new TPD therapies.

Request for a Discount on this Report Before Purchase:

https://www.polarismarketresearch.com/industry-analysis/targeted-protein-degradation-market/request-for-discount-pricing?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01

List of Targeted Protein Degradation Market Key Players

• Arvinas
• Kymera Therapeutics
• Nurix Therapeutics
• C4 Therapeutics
• Foghorn Therapeutics
• Zymeworks
• Bristol-Myers Squibb
• Pfizer
• AbbVie
• Molteni Farmaceutici

Geographical Analysis

North America accounted for the largest targeted protein degradation market share owing to its progressive healthcare framework, notable funding of biotechnology research, and a strong pipeline of clinical trials. The region’s supremacy is reinforced by the existence of spearheading pharmaceutical and biotechnology firms that are diligently advancing and commercializing inventive targeted protein degradation therapies.

Europe is also expected to grow at the highest CAGR during the forecast period. This is due to sizeable research and developmental ventures and a robust concentration on inventive therapeutics. The region profits from entrenched healthcare systems, collective research frameworks, and notable funding for biotechnology and pharmaceutical research. European nations are growingly funding customized medicines and earmarked therapies, causing the market’s expansion.

Inquire more about this report before purchase:

https://www.polarismarketresearch.com/industry-analysis/targeted-protein-degradation-market/inquire-before-buying?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01

Market Segmentation

By Type Outlook

• Degronimids
• Immunomodulatory Drugs (IMiDs)
• Proteolysis-Targeting Chimeric Molecules (PROTACs)
• Sudden Acquired Retinal Degeneration Syndrome (SARD)
• Selective Estrogen Receptor Degraders (SERDs)
• Others

By Therapeutic Area Outlook

• Inflammatory Disorders
• Neurological Disorders
• Oncological Disorders
• Respiratory Disorders
• Others

By Route of Administration Outlook

• Oral
• Intravenous
• Others

By Regional Outlook

• North America
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

More Trending Latest Reports by Polaris Market Research:

Animal Feed Market Share

Organic Food and Beverages Market Size

Cultured Meat Market Trends

Oat Milk Market Growth

Clean Label Ingredients Market Forecast

About Polaris Market Research & Consulting, Inc:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter